However, the detection of HMGCR antibodies, rapidly progressive proximal weakness, high CK, absence of DM-specific antibodies, and lack of pathognomonic cutaneous or systemic features led to a revised diagnosis of NAM. This evidence concerns the gene HMGCR and dermatomyositis.